12:00 AM
Feb 15, 2016
 |  BC Week In Review  |  Clinical News  |  Clinical Status

ALLN-177: Phase II started

Allena began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate 7,500 units of oral ALLN-177 thrice daily with meals for 28...

Read the full 89 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >